Cisplatin, ifosfamide, and vinorelbine combination chemotherapy in stage III-IV non-small-cell lung cancer: A phase II study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 5, 1998, Pages 518-522

  Rey, F ^a   Astoul, P ^b   Marqueste, L ^c   Petite, J M ^c   Boutin, C ^b   Viallat, J R ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b APHM and UMR S1076   (France)

^c Hopital Font Pre   (France)

Author keywords

Cisplatin; Dose intensity; Ifosfamide; Non small cell lung cancer; Phase II; Vinorelbine

Indexed keywords

CISPLATIN; IFOSFAMIDE; MESNA; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 0031724739     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199810000-00021     Document Type: Article

References (29)

1. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1866-72.
2. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
3. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest 1994;106:861-5.
4. Evans WK, Le Chevalier T. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer 1996;32:2249-55.
5. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
6. Dillman RO, Seagren SL, Propert KJ. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990;323:940-5.
7. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma [Letter]. J Natl Cancer Inst 1992;84:58.
8. Schaake-Konig C, van der Bogert W, Dalesio O. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992;326:524-30.
9. Masters GA, Yokes EE. Should non-small cell carcinoma of the lung be treated with chemotherapy? pro: chemotherapy is for non-small cell lung cancer. Am J Respir Crit Care Med 1995;151:1285-7.
10. Le Chevalier T, Brisgand D, Pujol JL, et al. Resultats d'une étude randomisée comparant l'association navelbine-cisplatin à l'association vindésine-cisplatinum et à la navelbine seule chez 612 malades porteurs d'un carcinome bronchique non à petites cellules inopérable. Bull Cancer (Paris) 1996;83:385-94.
11. Eberhardt W, Niederle N. Ifosfamide in non-small cell lung cancer: a review. Semin Oncol 1992;19(suppl 1):40-8.
12. Crawford J. Update: vinorelbine (navelbine) in non-small cell lung cancer. Semin Oncol 1996;23(suppl 5):2-7.
13. Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994;5:37-42.
14. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
15. Drings P. European experience with ifosfamide in non-small cell lung cancer. Semin Oncol 1989;16:22-30.
16. Frontini L, Candido P, Cattaneo MT, et al. Cisplatin-vinorelbine combination chemotherapy in locally advanced non-small cell lung cancer. Tumori 1996;82:57-60.
17. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990;8:1935-7.
18. Livingston RB. Dose intensity and high dose therapy, two different concepts. Cancer 1994;74:1177-83.
19. Bretti S, Berruti A, Gorzegno G, et al. Multicenter phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients. Lung Cancer 1996;14:353-60.
20. Graziano SL, Valone FH, Hemdon JE II, et al. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a cancer and leukemia group B study. Lung Cancer 1996;14:315-29.
21. Gebbia V, Galetta D, Majello E, Valenza R, Colucci G, Gebbia N. Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM). Am J Clin Oncol 1996;19:278-80.
22. Vallejo C, Romero A, Perez J, et al. Ifosfamide and Vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma. Am J Clin Oncol 1996;19:584-8.
23. Masters GA, Hoffman PC, Hsieh AL, et al. Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer. J Clin Oncol 1997;15:884-92.
24. Baldini E, Tibaldi C, Chella A, et al. Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. Ann Oncol 1996;7:747-9.
25. Barone C, Pozzo C, Cassano A, et al. Phase II study of vinorelbine, cisplatin and ifosfamide combination for advanced non-small cell lung cancer: preliminary results [Abstract]. Proceedings of the American Society of Clinical Oncology 1995;14:369.
26. Recchia F, De Filippis S, Lococo A, Vaccarili M, Terenzi S, Campisi C. Phase II study of navelbine (NVB), ifosfamide (IFO) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC) [Abstract]. Proceedings of the American Society of Clinical Oncology 1996;15:371.
27. Souquet PJ, Fournel P, Bohas CH, Fortune IC, Chatte G. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer. Semin Oncol 1996;23(suppl 5):8-10.
28. Poudenx JO, Ferrero JM, Frenay M, et al. Vinorelbine (VNR), ifosfamide (IFX) and cisplatin (CDDP) in non-small cell lung cancer (NSCLC). preliminary report [Abstract]. Proceedings of the American Society of Clinical Oncology 1995;14:366.
29. Tan EH, Ana PT, Wee J, Khoo KS. Navelbine (NVB), ifosfamide (IFO), and cisplatin (CDDP) in advanced non-small cell lung cancer (NSCLC): NIP [Abstract]. Lung Cancer 1997;18(suppl 1):47.